Literature DB >> 19562293

Preoperative total serum cholesterol as a prognostic factor for survival in patients with resectable non-small-cell lung cancer.

Mihael Sok1, Janez Ravnik, Maja Ravnik.   

Abstract

BACKGROUND: Coexisting hypocholesterolemia in cancer has been known for a very long time but its relationship to cancer is still controversial. Hypocholesterolemia has been reported in patients with lung cancer, although its association with survival has not been explored.
OBJECTIVES: The purpose of the study was to determine whether preoperative total serum cholesterol is a prognostic factor for survival after lung cancer resection.
METHODS: The retrospective study comprised 198 patients (162 men, 36 women) operated upon for resectable non-small-cell lung cancer (clinical stages I-IIIB) between January 1992 and April 1994. Total serum cholesterol concentration was determined preoperatively in each patient. The effects of sex, age, stage, histological type and preoperative total serum cholesterol concentration on survival were tested in univariate and multivariate analysis.
RESULTS: Preoperative total serum cholesterol was a significant prognostic factor in both univariate and multivariate analysis. The median value for total serum cholesterol was 5.3 mmol/l and patients below that cut-off had significantly shorter overall survival times than patients in the high cholesterol group (5-year survival 41% vs. 56%, P < 0.05). In a multivariate Cox proportional-hazard regression model, only stage and preoperative total serum cholesterol were found to be of significance for survival (relative risk 0.84 for each mmol/l increase in concentration, CI 0.71-1.00, P < 0.05).
CONCLUSIONS: Our results suggest that preoperative total serum cholesterol may be an important prognostic factor for overall survival after lung cancer resection. It may prove to be a valuable tool in the follow-up of patients with lung cancer and in detection of high-risk cases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19562293     DOI: 10.1007/s00508-009-1169-8

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  22 in total

1.  The effect of interferon on the metabolism of LDLs.

Authors:  G Schectman; S Kaul; R A Mueller; E C Borden; A H Kissebah
Journal:  Arterioscler Thromb       Date:  1992-09

Review 2.  [Expert recommendations 2006 on the rationale for second-line therapy for non-small cell bronchial neoplasms].

Authors:  Wolfgang Hilbe; Kurt Aigner; Christian Dittrich; Josef Eckmayr; Michael Fiegl; Martin Flicker; Bernhard Forstner; Richard Greil; Herbert Jamnig; Gerhard Krajnik; Alois Lang; Andrea Mohn-Staudner; Herwig Schinko; Michael Studnicka; Robert Pirker; Ferdinand Ploner; Johannes Rothmund; Lothar Schiller; August Zabernigg; Sabine Zöchbauer-Müller
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

3.  Immune system differences in men with hypo- or hypercholesterolemia.

Authors:  M F Muldoon; A Marsland; J D Flory; B S Rabin; T L Whiteside; S B Manuck
Journal:  Clin Immunol Immunopathol       Date:  1997-08

4.  Stimulation of low density lipoprotein receptor activity by conditioned medium from a human cancer cell line.

Authors:  O Shiroeda; N Yamaguchi; K Kawai
Journal:  Cancer Res       Date:  1987-09-01       Impact factor: 12.701

5.  Prospective study of serum cholesterol and site-specific cancers.

Authors:  P H Chyou; A M Nomura; G N Stemmermann; I Kato
Journal:  J Clin Epidemiol       Date:  1992-03       Impact factor: 6.437

6.  Decreased feedback regulation of low density lipoprotein receptor activity by sterols in leukemic cells from patients with acute myelogenous leukemia.

Authors:  L Tatidis; A Gruber; S Vitols
Journal:  J Lipid Res       Date:  1997-12       Impact factor: 5.922

Review 7.  The endotoxin-lipoprotein hypothesis.

Authors:  M Rauchhaus; A J Coats; S D Anker
Journal:  Lancet       Date:  2000-09-09       Impact factor: 79.321

8.  The relationship between cholesterol and survival in patients with chronic heart failure.

Authors:  Mathias Rauchhaus; Andrew L Clark; Wolfram Doehner; Constantinos Davos; Aidan Bolger; Rakesh Sharma; Andrew J S Coats; Stefan D Anker
Journal:  J Am Coll Cardiol       Date:  2003-12-03       Impact factor: 24.094

9.  Serum cholesterol and cancer in the NHANES I epidemiologic followup study. National Health and Nutrition Examination Survey.

Authors:  A Schatzkin; R N Hoover; P R Taylor; R G Ziegler; C L Carter; D B Larson; L M Licitra
Journal:  Lancet       Date:  1987-08-08       Impact factor: 79.321

10.  Enhancement of the antigen-presenting function of monocytes by cholesterol: possible relevance to inflammatory mechanisms in extrinsic allergic alveolitis and atherosclerosis.

Authors:  D A Hughes; P J Townsend; P L Haslam
Journal:  Clin Exp Immunol       Date:  1992-02       Impact factor: 4.330

View more
  14 in total

1.  COPD is not COPD is not allergy.

Authors:  Stanislav Suskovic
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

2.  Risk factors and clinical courses of chemoradiation-related arterio-esophageal fistula in esophageal cancer patients with clinical invasion of the aorta.

Authors:  Hiroya Taniguchi; Kentaro Yamazaki; Narikazu Boku; Taro Funakoshi; Satoshi Hamauchi; Takahiro Tsushima; Akiko Todaka; Takeshi Sakamoto; Hideharu Tomita; Nozomu Machida; Keisei Taku; Akira Fukutomi; Yusuke Onozawa; Yasuhiro Tsubosa; Hiroshi Sato; Tetsuo Nishimura; Hirofumi Yasui
Journal:  Int J Clin Oncol       Date:  2011-02-24       Impact factor: 3.402

3.  Decreased pretreatment serum cholesterol level is related with poor prognosis in resectable non-small cell lung cancer.

Authors:  Jin-Rui Li; Ye Zhang; Jia-Lian Zheng
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

4.  Preoperative Total Serum Cholesterol and Patients' Survival in Resected Nonsmall Cell Lung Cancer.

Authors:  Masaki Tomita; Takanori Ayabe; Tetsuya Shimizu; Kunihide Nakamura
Journal:  Lung Cancer Int       Date:  2012-11-26

5.  Serum adiponectin relates to shortened overall survival in men with squamous cell esophageal cancer treated with preoperative concurrent chemoradiotherapy: a pilot study.

Authors:  Milada Zemanová; Barbora Staňková; Zuzana Ušiakova; Eva Tvrzická; Alexandr Pazdro; Luboš Petruželka; Miroslav Zeman
Journal:  Med Sci Monit       Date:  2014-11-19

6.  The pretreatment Controlling Nutritional Status (CONUT) score is an independent prognostic factor in patients with resectable thoracic esophageal squamous cell carcinoma: results from a retrospective study.

Authors:  Takahiro Toyokawa; Naoshi Kubo; Tatsuro Tamura; Katsunobu Sakurai; Ryosuke Amano; Hiroaki Tanaka; Kazuya Muguruma; Masakazu Yashiro; Kosei Hirakawa; Masaichi Ohira
Journal:  BMC Cancer       Date:  2016-09-06       Impact factor: 4.430

7.  Impact of coexisting pulmonary diseases on survival of patients with lung adenocarcinoma: a STROBE-compliant article.

Authors:  Zhi-Hong Jian; Jing-Yang Huang; Pei-Chieh Ko; Shiou-Rung Jan; Oswald Ndi Nfor; Chia-Chi Lung; Wen-Yuan Ku; Chien-Chang Ho; Hui-Hsien Pan; Yung-Po Liaw
Journal:  Medicine (Baltimore)       Date:  2015-01       Impact factor: 1.889

8.  CONUT Score or/and Peripheral Blood CD4+/CD8+ Ratio-Based Web Dynamic Nomograms to Predict the Individualized Survival of Patients with Advanced Osteosarcoma.

Authors:  Qian-Kun Yang; Yan-Na Su; Wei Wang; Zhong-Xiang Yao; Nan Wang; Xiao-Jing Zhang
Journal:  Cancer Manag Res       Date:  2020-06-03       Impact factor: 3.989

9.  The Practicability of a Novel Prognostic Index (PI) Model and Comparison with Nottingham Prognostic Index (NPI) in Stage I-III Breast Cancer Patients Undergoing Surgical Treatment.

Authors:  Jiahuai Wen; Feng Ye; Shuaijie Li; Xiaojia Huang; Lu Yang; Xiangsheng Xiao; Xiaoming Xie
Journal:  PLoS One       Date:  2015-11-23       Impact factor: 3.240

10.  Clinical significance of pre-surgical serum lipid levels in patients with glioblastoma.

Authors:  Ruofei Liang; Junhong Li; Mao Li; Yuan Yang; Xiang Wang; Qing Mao; Yanhui Liu
Journal:  Oncotarget       Date:  2017-09-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.